Amrecibart and cenvacibart both substantially reduced venous thrombosis rates after peripherally inserted central catheter (PICC) use, according to new data from the ROXI-CATH trial.1 These data were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, by Gregory Piazza, MD, MS, a cardiovascular medicine specialist at Brigham and Women’s Hospital and an associate professor of medicine at Harvard Medical School.1 “In practice, in the setting of...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Gregory
Contact Gregory, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack